Voyager Therapeutics

VYGR

Market cap $296M

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Citi's Biopharma Back to School Conference September 2, 2025 4:00 PM EDT Company Participants Alfred Sandrock - President, CEO & Director Todd Carter - Chief Scientific Officer Nathan Jorgensen - CFO, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President I'm Sam Semenkow, one of the biotech analysts here at Citi, and it's my pleasure to be hosting Voyager Therapeutics. I'm joined by Al Sandrock, President and CEO; Nate Jorgensen, CFO; Todd Carter, CSO; and Trista Morrison, Chief of Communications.

LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.18 per share a year ago.

- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise - - 11 partnered programs with potential for $2.6B in development-stage milestone payments - LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2025 financial and operating results.

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant -

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled “Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier,” was published in Molecular Therapy and can be accessed here.

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.20 per share a year ago.

– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg –